Tumor necrosis factor in CHF: A double facet cytokine

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 554-559

  Ferrari, Roberto ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS   (Italy)

Author keywords

Cachexia; Chronic heart failure; Cytokines; Tumor necrosis factor

Indexed keywords

CYTOKINE; LYMPHOTOXIN; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CACHEXIA; CONGESTIVE HEART FAILURE; CYTOTOXICITY; EDITORIAL; HEART FAILURE; HEART VENTRICLE FUNCTION; INFLAMMATION; MUSCLE ATROPHY; PRIORITY JOURNAL;

ANIMALS; DINOPROSTONE; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; HUMANS; MICE; MYOCARDIUM; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032029131     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00309-X     Document Type: Editorial

References (52)

1. [1] Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-632.
2. [2] Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 1988;57:505-518.
3. [3] Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the decade. Eur Cytokine Netw 1996;72:93-124.
4. [4] Spiegelman BM, Hotamisligil GS. Through thick and thin: wasting, obesity and TNF-α. Cell 1993;73:625.
5. [5] Vassalli P. The pathophysiology of tumor necrosis factor. Annu Rev Immunol 1992;10:411-452.
6. [6] Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-399.
7. [7] Habib FM, Springall DR, Davies GJ, Oakley CM, Yacub MH, Polak JM. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151-1153.
8. [8] Maury CPJ, Teppo AM. Circulating tumor necrosis factor-α (cachetin) in myocardial infarction. J Intern Med 1989;225:333-336.
9. [9] Boldin MP, Mett IL, Varfolomeev EE, et al. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO-1 prompts signaling for TNF and Fas/APO-1 effect. J Biol Chem 1995;270:387-391.
10. [10] Katz A, Katz PB. Diseases of the heart in works of Hippocrates. Br Heart J 1962;24:257-264.
11. [11] Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 1990;323:236-241.
12. [12] McMurray J, Abdullh I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991;66:356-358.
13. [13] Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor α in severe congestive cardiac failure. Br Heart J 1993;70:141-143.
14. [14] Katz SD, Rao R, Berman JW, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994;90:12-16.
15. [15] Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-566.
16. [16] Wiedermann CJ, Bermpold H, Manfred H, Knapp E, Braunstein H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993;22:1897-1901.
17. [17] Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res 1992;70:856-863.
18. [18] Arbustini E, Grasso M, Diegoli M, et al. Expression of tumor necrosis factor in human acute cardiac rejection: an immunohistochemical and immunoblotting study. Am J Pathol 1991;139:709-715.
19. [19] Jansen JN, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992;54:744-748.
20. [20] Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1996;92:1479-1486.
21. [21] Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711.
22. [22] Latini R, Bianchi M, Correale E, et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994;23:1-6.
23. [23] Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?. Circulation 1995;92:1379-1382.
24. [24] Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-329.
25. [25] Kapadia S, Torre-Amione G, Yokoyama T, Mann DL. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am J Physiol 1995;268:H517-H525.
26. [26] Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA. Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes: regulation of L-arginine transport and NO production by CAT-1, CAT-2A, and CAT-2B. J Biol Chem 1996;271:11694-11702.
27. [27] Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA. Glucocorticoids regulate inducible nitric oxide synthase (NOS2) by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem 1996;271:23928-23937.
28. [28] Nathan C. Natural resistance and nitric oxide. Cell 1995;82:873-876.
29. [29] Ferrari R, Comini L, Bachetti T, et al. Expression of inducible NO-synthase in the monocytes and tumor necrosis factor activation in patients with congestive heart failure. Am Heart J 1997; submitted for publication.
30. [30] Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-10894.
31. [31] Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997;95:778-781.
32. [32] Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996;79:363-380.
33. [33] Ungureanu-Longrois D, Balligand JL, Kelly RA, Smith TW. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol 1995;27:155-167.
34. [34] Campbell DL, Stamler JS, Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes: mechanisms of dual indirect and direct modulation by nitric oxide and S-nitrosothiols. J Gen Physiol 1996;108:277-293.
35. [35] Gross WL, Bak MI, Ingwall JS, et al. Nitric oxide regulates rat heart contractile reserve and inhibits creatine kinase. Proc Natl Acad Sci USA 1996;93:5604-5609.
36. [36] Murray DR, Freeman GL. Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1996;78:154-160.
37. [37] Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-389.
38. 2+) and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996;271:H1449-H1455.
39. [39] Yamamoto S, Tsutsui H, Tagawa H, et al. Role of myocyte nitric oxide in β-adrenergic hyporesponsiveness in heart failure. Circulation 1997;95:1111-1114.
40. [40] Szaboles M, Michler RE, Yang X, et al. Apoptosis of cardiac myocytes during cardiac allograft rejection: relation to induction of nitric oxide synthase. Circulation 1996;94:1665-1673.
41. [41] Gravanis MB, Kanter KR, Kassen M, Mayne A, Ansari AA. Semiquantitative assessment of apoptotic cells in cardiac tissue of patients with cardiomyopathies. Circulation 1994;90:584-589.
42. [42] Olivetti G, Abbi R, Quaini F, Kajstura K, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami C, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141.
43. [43] Poole-Wilson P, Ferrari R. Role of skeletal muscle in the syndrome of chronic heart failure. J Mol Cell Cardiol 1996;28:2275-2285.
44. [44] Wilson JR, Mancini DM. Factors contributing to the exercise limitation of heart failure. J Am Coll Cardiol 1993;22:93A-98A.
45. [45] Ferrari R, Agnoletti L, Comini L, Gaia G, Bachetti T, Cargnoni A, Ceconi C, Curello S, Visioli O. Oxidative stress during myocardial ischemia and heart failure. Eur Heart J, in press.
46. [46] Kroemer G, Petit P, Zamzami N, Vayessiere JL, Mignotte B. The biochemistry of programmed cell death. Faseb J 1995;9:1277-1287.
47. [47] Robaye B, Mosselmans R, Fiers W, Dumont JE, Galand P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cell in vitro. Am J Pathol 1991;138:447-453.
48. [48] Agnoletti L, Malacarne F, Comini L, et al. Increased FAS expression and apoptosis of lymphocytes from patients with severe congestive heart failure. IV National Congress of the Italian Society for Cardiovascular Research. Rimini: May, 1997;6 (abstract).
49. [49] Ferrari R, Corti A, Bachetti T. Tumor necrosis factor alpha in heart failure. Heart Failure 1995;11:142-149.
50. [50] Smith JJ, Shapiro L, Dolan NA, et al. Cytokine antagonists circulate in the blood of patients with advanced congestive heart failure. J Am Coll Cardiol 1993;21:268A. abstract.
51. [51] Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-352.
52. [52] Anker SD, Egerer KR, Volk H, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:1426-1430.